Study of Cisplatin and Pemetrexed in Combination With Panobinostat in Solid Tumors
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01336842 |
Recruitment Status :
Completed
First Posted : April 18, 2011
Last Update Posted : January 9, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Solid Tumors Non-Small Cell Lung Cancer (NSCLC) | Drug: Panobinostat, Cisplatin, Pemetrexed | Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 23 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Phase I Trial of Cisplatin and Pemetrexed in Combination With Panobinostat in Advanced Solid Tumors, With Emphasis on Non-Small Cell Lung Cancer |
Study Start Date : | April 2011 |
Actual Primary Completion Date : | January 2017 |
Actual Study Completion Date : | June 2017 |

Arm | Intervention/treatment |
---|---|
Experimental: Phase I dose-escalation
Drug: panobinostat Drug: cisplatin Drug: pemetrexed Other: Biomarker studies
|
Drug: Panobinostat, Cisplatin, Pemetrexed
Drug: Panobinostat Oral (by mouth) once daily every Monday, Wednesday, and Friday for the first two weeks of each three week cycle (as per dose escalation schedule (dose levels 1 and 2: AUC 5; dose levels 3 and 4: AUC 6). Number of cycles: 6 maximum. Drug: Cisplatin IV (in the vein) on day 1 of a 21-day cycle Number of cycles: 6 maximum. Drug: Pemetrexed IV (in the vein) on day 1 of a 21-day cycle Other: Correlative studies Biomarker Analysis: blood collected pre-study and Cycles 2-6, Day 1. Other Names:
|
- Safety and feasibility of oral panobinostat in combination with cisplatin and pemetrexed [ Time Frame: Within ±3 days of the scheduled day of assessment except for adverse events that will be evaluated continuously through the study. The expected time frame for this outcome measure is 18 weeks (or six cycles) ]Safety assessments will consist of monitoring and recording all adverse events and serious adverse events, the regular monitoring of hematology, blood chemistry and urine values, regular measurement of vital signs and the performance of physical examination. Safety and tolerability will be assessed according to the NCI CTCAE v4.
- Maximum-tolerated dose as assessed by NCI CTCAE, Version 4.0 [ Time Frame: 3 week cycle; the expected time frame is 18 weeks (or 6 cycles) ]Determination of maximum tolerated dose (MTD) will be based on cycle 1 toxicities
- Dose-limiting toxicities and toxicity profile as assessed by NCI CTCAE, Version 4.0 [ Time Frame: 3 week cycle; the expected time frame is 18 weeks (or 6 cycles) ]Dose-limiting toxicity (DLT) will be based on cycle 1 toxicities.
- Exploratory biomarker analysis [ Time Frame: Blood specimens will be collected prior to treatment, prior to Cycles 2-6. In addition, a blood specimen will be collected if the patient is removed from the study due to progression of disease. the expected time frame is 18 weeks (or 6 cycles) ]Molecular markers predictive for response to panobinostat remain unknown. This trial offers the opportunity to retrospectively study biomarkers and their association with clinical outcomes.
- Efficacy of oral panobinostat in combination with cisplatin/pemetrexed in an expanded cohort of patients with NSCLC [ Time Frame: CT scans will be performed at baseline and every two cycles; the expected time frame is 18 weeks (or 6 cycles) ]Response rate will be assessed by CT scan. CT scans will be performed at baseline and every two cycles. The evaluation of response will be based on standard RECIST criteria.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Histological or cytological proven advanced solid tumors for which curative standard treatments are not available.
- Must have measurable or evaluable disease.
- Male or female patients aged ≥ 18 years old.
- Any number of prior chemotherapy regimens.
- ECOG Performance Status of ≤ 2 with a life expectancy greater than 3 months.
- Clinically euthyroid (may be on thyroid hormone replacement)
- Women of childbearing potential (WOCBP) must have a negative serum pregnancy test within 7 days of the first administration of study treatment.
- Ability to provide written informed consent
- Must meet the following laboratory criteria:
Hematology:
- Neutrophil count of ≥ 1.5 x 109/L
- Platelet count of ≥ 100 x 109/L
- Hemoglobin ≥ 9 g/dL
Biochemistry:
- AST/SGOT and ALT/SGPT ≤ 2.5 x upper limit of normal (ULN) or ≤ 5.0 x ULN if the transaminase elevation is due to disease involvement
- Serum bilirubin ≤ 1.5 x ULN
- Serum creatinine ≤ 1.5 x ULN or 24-hour creatinine clearance ≥ 50 ml/min
- Total serum calcium (corrected for serum albumin) or ionized calcium ≥ LLN and ≤ ULN
- Serum potassium ≥ LLN and ≤ ULN
- Serum sodium ≥ LLN and ≤ ULN
- Serum albumin ≥ LLN or 3g/dl
- Serum magnesium ≥ LLN and ≤ ULN
- Any elevated Alkaline Phosphatase due to bone metastasis can be enrolled
Exclusion Criteria:
- Prior HDAC, DAC, HSP90 inhibitors or valproic acid for the treatment of cancer.
- Patients who will need valproic acid for any medical condition during the study or within 5 days prior to first panobinostat treatment.
- Patients who have received chemotherapy, any investigational drug or undergone major surgery < 4 weeks prior to starting study drug or who have not recovered from side effects of such therapy.
- Impaired cardiac function
- Other concurrent severe and/or uncontrolled medical conditions that could cause unacceptable safety risks or compromise compliance with the protocol
- Concomitant use of drugs which are generally recognized to have a risk of causing torsades de pointes where such treatment cannot be discontinued or switched to a different medication prior to starting study drug
- Patients with unresolved diarrhea ≥ CTCAE grade 2
- Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral panobinostat. Inability to swallow panobinostat capsules whole.
- Concomitant use of any anti-cancer therapy or radiation therapy
- Uncontrolled or symptomatic brain metastases.
- Women who are pregnant or breast feeding or women of childbearing potential (WOCBP) not willing to use a double barrier method of contraception during the study and 3 months after the end of treatment. One of these methods of contraception must be a barrier method. WOCBP are defined as sexually mature women who have not undergone a hysterectomy or who have not been naturally postmenopausal for at least 12 consecutive months (i.e., who has had menses any time in the preceding 12 consecutive months).
- Male patients whose sexual partners are WOCBP not using a double method of contraception during the study and 3 months after the end of treatment.
- Known positivity for human immunodeficiency virus (HIV) or hepatitis C; baseline testing for HIV and hepatitis C is not required
- Any significant history of non-compliance to medical regimens or with inability to grant a reliable informed consent

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01336842
United States, California | |
University of California Davis Cancer Center | |
Sacramento, California, United States, 95817 | |
United States, Michigan | |
Henry Ford Health System | |
Detroit, Michigan, United States, 48202 |
Principal Investigator: | David Gandara, MD | University of California, Davis |
Responsible Party: | University of California, Davis |
ClinicalTrials.gov Identifier: | NCT01336842 |
Other Study ID Numbers: |
UCDCC#220 222274 ( Other Identifier: UC Davis ) CLBH589BUS31T ( Other Identifier: Novartis ) |
First Posted: | April 18, 2011 Key Record Dates |
Last Update Posted: | January 9, 2018 |
Last Verified: | January 2018 |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
panobinostat cisplatin pemetrexed dose escalation |
Lung Neoplasms Carcinoma, Non-Small-Cell Lung Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site Neoplasms Lung Diseases Respiratory Tract Diseases Carcinoma, Bronchogenic Bronchial Neoplasms |
Cisplatin Pemetrexed Panobinostat Antineoplastic Agents Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Folic Acid Antagonists Nucleic Acid Synthesis Inhibitors Histone Deacetylase Inhibitors |